Navigation Links
Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
Date:8/15/2008

SHENZHEN, China, Aug. 15 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide announced today that Mindray will be attending the Morgan Stanley Global Healthcare Unplugged Conference in New York, NY on September 8th & 9th, 2008.

The conference will be attended by Mr. Hang Xu, Mindray's chairman and co- chief executive officer, Joyce I-Yin Hsu, Mindray's chief financial officer, Minghe Cheng, executive vice president of strategic development, Ronald Ede, Group Vice President of International Operations, and May Li, head of investor relations. Mr. Hang Xu will be presenting on behalf of Mindray.

The Morgan Stanley Global Healthcare Unplugged Conference will take place at the Grand Hyatt New York on Monday, September 8 and Tuesday, September 9, 2008. Mr. Hang Xu will be presenting on Tuesday, September 9 at 10:20 am EST.

For more details on Morgan Stanley's Global Healthcare Unplugged Conference, please visit http://www.morganstanley.com/conferences/EV0007155.html .

About Mindray

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has another 12 international sales and service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver.

For more information, please visit http://www.mindray.com .

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about Mindray's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Information regarding these risks and uncertainties is included in our public filings with the Securities and Exchange Commission. All information provided in this press release is as of July 17, 2008, and Mindray undertakes no duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

In the U.S:

Evan Smith,

FD

Tel: +1-212-850-5606

Email: evan.smith@fd.com

John Capodanno,

FD

Tel: +1-212-850-5705

Email: john.capodanno@fd.com

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: Susan.Du@Mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mindray Medical International Announces First Quarter 2008 Results
2. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
3. Mindray Medical International Announces Third Quarter 2007 Results
4. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
5. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
6. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
7. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
10. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
11. BioMS Medical Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):